Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Nasopharyngeal Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: To determine the clinical efficacy of apatinib mesylate tablets combined with PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma. SECONDARY OBJECTIVES: ?.To explore the adjuvant medication regimen of recurrent and metastatic nasopharyngeal carcinoma. ?.Pro...
PRIMARY OBJECTIVES: To determine the clinical efficacy of apatinib mesylate tablets combined with PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma. SECONDARY OBJECTIVES: ?.To explore the adjuvant medication regimen of recurrent and metastatic nasopharyngeal carcinoma. ?.Provide high-level evidence-based medical evidence for the new individualized treatment strategy of nasopharyngeal carcinoma patients. OUTLINE: Eligible patients begin to use apatinib mesylate tablets and PD-1, apatinib mesylate tablets at the recommended dose of 250mg,orally, QD, continuous administration, 4 weeks (28 days) as an observation cycle. Until the disease progressed or unbearable adverse reactions appeared. If missed medication occurs during the medication period, it is confirmed that the next medication time is less than 12 hours, then there will be no replenishment. The recommended dose of PD-1 is 200mg/time, Q2W, intravenous injection, 4 weeks (28 days) as an observation cycle, until disease progression or intolerable toxicity.
Tracking Information
- NCT #
- NCT04350190
- Collaborators
- Wuzhou Red Cross Hospital
- Guangxi Naxishan Hospital
- People's Hospital of Laibin
- People's Hospital of Lingshan
- Investigators
- Study Director: Wei Jiang, Ph.D. Guilin Medical University, China